TAGline November 2024
This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.
1/4/6×24 Campaign Concerned Prices Hinder Uptake of Important Updated World Health Organization Drug-Resistant TB Treatment Recommendations
The 1/4/6x24 Campaign warns that regimens to treat drug-resistant TB recently recommended by World Health Organization (WHO) and important diagnostic tools will remain out of reach due to high prices.
Finally, Children of All Ages Can Benefit from 3HP to Prevent TB!
The Community Research Advisors Group (CRAG) celebrates both the findings and the methodology of Study 35, a phase I/II clinical trial of the tuberculosis (TB) preventive treatment regimen known as 3HP in children.
Statement from TAG’s TB Project on Today’s WHO Global TB Report Release
Treatment Action Group (TAG) is deeply concerned by the reported decrease in domestic funding for tuberculosis (TB) services announced today in the World Health Organization's 2024 Global Tuberculosis Report.
2023 Annual Report
We're pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.
TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing
On May 15, 2024, TAG hosted this webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.
An Activist’s Guide to Rifapentine – TB Preventive Treatment: 3HP and 1 HP
Rifapentine, an off-patent drug that's been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.
1/4/6×24 Mid-Campaign Report Launch Webinar
On March 27, 2024, the 1/4/6x24 Campaign and the Stop TB Partnership co-hosted a webinar to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments.
Mid-Campaign Report Highlights What’s Needed to Win Better, Shorter TB Treatments for All by End of 2024
Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6x24 Campaign coalition has found.
Getting Better Faster: Delivering on the Promise of New TB Treatments – A Report from the 1/4/6×24 Campaign
This report marks the midway point of the 1/4/6x24 Campaign, which calls for the universal implementation of best available TB regimens — as little as one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.